Hikma to reduce global footprint

Hikma intends to reduce its geographic footprint from its current presence in around 50 countries worldwide, especially by focusing resources on only the most promising markets in the Middle East and North Africa (MENA) region, under a corporate strategy presented by Siggi Olafsson, who became chief executive officer around nine months ago. Olafsson also wants to treble the group’s return on research and development investment within the next five years.

Hikma intends to reduce its geographic footprint from its current presence in around 50 countries worldwide, especially by focusing resources on only the most promising markets in the Middle East and North Africa (MENA) region, under a corporate strategy presented by Siggi Olafsson, who became chief executive officer around nine months ago. Olafsson also wants to treble the group’s return on research and development investment within the next five years.

Stressing Hikma’s differentiating factor of being “the only global local player” in the MENA region, Olafsson said the firm was...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from Generics Bulletin

Kirsty Gives Biocon A First Interchangeable US Insulin Aspart Biosimilar

 
• By 

After years of waiting, Biocon Biologics has finally snagged US FDA approval for its insulin aspart biosimilar – along with a first designation of interchangeability. However, Sanofi’s Merilog version is already approved as a rival to Novo Nordisk’s Novolog.

MSN’s Entresto Generic Temporarily Blocked As Key US Patent Expires

 
• By 

The Federal Circuit has temporarily blocked MSN from launching a generic version of Entresto, granting Novartis short-term relief while it reviews the company’s emergency Rule 8 motion for a longer injunction.

Making The UK A Leading Biosimilar Launch Destination – Realistic Or Optimistic?

 

Experts discussed the UK government’s commitment to make the country a desirable destination for companies to launch their biosimilars at a recent conference hosted by Medicines UK.